The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Furthermore, those diagnosed with marijuana addiction before they were stricken with colon cancer were 24.4 times more likely ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

“The findings offer the first real solution in two decades for managing this rash, which frequently impacts patients receiving targeted therapies for colorectal cancer,” said study co-author ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

Colon cancer is on the rise among young adults in the U.S. New research finds regular exercise can help survivors live longer - in some cases, even longer than people who haven't had colon cancer.

Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

When it comes to colon cancer, the good news is that overall, death rates have been falling thanks to improvements in screening and treatment. But survivors still tend to have a shorter life ...